Women spend roughly a third of their lives after menopause, yet the biology that connects this transition to brain health decades later is poorly understood. A new study in Nature Medicine, led by researchers at UC Santa Barbara, UC San Francisco and the Sunnybrook Research Institute in Canada, takes a step toward filling that gap. By measuring thousands of proteins in the blood, the team found a molecular signature of menopause that overlaps with markers of brain aging and dementia risk.
Looking at thousands of proteins at once
The
researchers used proteomics, a technology that measures large numbers of
proteins in a sample. They applied it to pre-, peri- and postmenopausal women
from the Healthy Aging Study run by the Jacobs Lab at UCSB, a project designed
to investigate brain and cognitive function in women and men in midlife. They
identified a set of proteins that change across the menopause transition,
including proteins involved in inflammation and neuronal processes, as well as
molecules associated with Alzheimer’s disease.
Two details stand out. First, the changes tracked a woman’s menopause stage more closely than her exact age, which suggests that menopause itself, and not only the passage of time, drives them. Second, the pattern held up in a separate dataset of more than 2,800 women from the UK Biobank, where menopause was also tied to molecular signatures of accelerated aging across several organ systems. In total, the team reported higher levels of 16 molecules implicated in brain aging and dementia risk.
Connecting the signature to later-life brain health
The next question was whether this midlife signature relates to what happens in the brain later. Using data from four independent cohorts totaling nearly 12,000 older women, the researchers found that women with higher levels of these risk-associated proteins were more likely to have poorer cognitive outcomes. In the largest cohort, the signature was also linked to a modestly higher risk of developing Alzheimer’s dementia over the following 16 years.
The long-term goal: an early-warning blood test
The team hopes to develop a blood test that could flag dementia risk in midlife, much as cholesterol tests are used to gauge heart disease risk. Such a test could help clinicians identify people who might benefit from early interventions, at a stage when, as senior author Kaitlin Casaletto describes it, the brain can be set up to be either more resilient or more vulnerable to dementia later on.
What this does not show
The authors
themselves stress that these findings do not mean menopause causes Alzheimer’s
disease. Most women do not develop it, and the clinical meaning of individual
Alzheimer’s-related protein changes detected in midlife remains uncertain. The
reported association with Alzheimer’s dementia risk was modest, and the study
identifies a risk signature, not a diagnostic test or a treatment. The
researchers note that longitudinal studies following the same women through the
menopause transition are needed to understand how hormones, proteins, symptoms
and brain health change together over time. Their group is now launching the
Longitudinal Menopause Project for that purpose.
The study was led by Madeline Wood Alexander (Sunnybrook Research Institute) and Rowan Saloner and Kaitlin Casaletto (UCSF), with collaborators from UCSB, Stanford, the University of Toronto and other institutions. Funding included support from the Ann S. Bowers Women’s Brain Health Initiative, Wellcome Leap, the National Institutes of Health and the Noyce Trust.
Sources
·
Press release (University of
California, Santa Barbara, via EurekAlert!, November 2, 2026): Blood proteins reveal
how menopause may shape brain health later in life
·
Journal article (Nature Medicine,
published September 22, 2026): Blood proteomics of
menopause map to brain aging and dementia risk
·
Original source of the press
release: UC
Santa Barbara news
Source: A Molecular Fingerprint of Menopause in the Blood Links to Brain Aging and Dementia Risk
No comments:
Post a Comment